Robust Revenue Growth
SI-BONE, Inc. reported worldwide revenue of $48.7 million in Q3 2025, representing a 20.6% growth year-over-year. U.S. revenue increased by 21.2% to $46.4 million, driven by procedure volume growth of over 22%.
Positive Adjusted EBITDA and Cash Flow Milestones
The company achieved positive adjusted EBITDA of $2.3 million for the quarter with an adjusted EBITDA margin of approximately 5%. They also reported their first quarter of meaningful positive cash flow from operating activities.
Physician Engagement and Expansion
In Q3 2025, approximately 1,530 physicians performed procedures using SI-BONE's solutions, marking a 27% year-over-year increase. The company added 330 physicians in the quarter, the largest quarterly increase in its history.
International Growth and Product Launches
The launch of iFuse Torque in Europe contributed to international revenue growth of 10.2%. Additionally, the company filed a 510(k) application for next-generation technology and received FDA 510(k) clearance for instruments enhancing procedural flexibility.
Market Expansion and New Products
SI-BONE is planning to launch several innovative products, including a new SI joint fusion product in Q1 2026 and a breakthrough device targeting spine surgery later in 2026.